Source: PIB Delhi |10 March 2026|
What is Biopharma SHAKTI?
The Biopharma SHAKTI scheme is a flagship government initiative aimed at transforming India into a world-class hub for the manufacturing and innovation of biologics and biosimilars. Announced with a financial outlay of ₹10,000 crore over five years, the scheme seeks to create a globally competitive domestic ecosystem in the biopharmaceutical space.
The term SHAKTI is aligned with the broader philosophy of building strength — in terms of research, infrastructure, regulation, and innovation — within India's pharmaceutical sector. The scheme was disclosed by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, through a written reply in the Rajya Sabha on March 10, 2026.
Why Is This News Important?
Biopharma SHAKTI is not just a health scheme — it is a national economic, strategic, and public health milestone. Here's why it matters:
Biologic medicines for cancer, diabetes, and autoimmune conditions are among the costliest treatments globally. By building domestic manufacturing capacity, India can slash these costs dramatically, making life-saving biologics and biosimilars accessible to millions who currently cannot afford them.
India's over-reliance on imported biologics is a strategic vulnerability — as seen during COVID-19, when global supply chains were disrupted. This scheme directly builds India's self-reliance in high-value pharmaceuticals, strengthening national health security.
The global biosimilars market alone is expected to reach $100 billion by 2030. With its existing pharmaceutical prowess, cost competitiveness, and skilled workforce, India is well-positioned to capture a major share of this market. Biopharma SHAKTI can generate billions in export revenue and create lakhs of high-skill jobs.
The scheme is a natural extension of India's Atmanirbhar Bharat and Make in India visions — transitioning the country from being a manufacturer of low-cost generic drugs to a sophisticated, high-value biopharma innovator on the global stage.
By adding three new NIPERs and upgrading seven existing ones, the scheme addresses the critical bottleneck of human resources. India currently lacks the critical mass of trained biopharma scientists, regulatory experts, and clinical trial specialists — this investment directly fills that gap.
Slow regulatory timelines at CDSCO have historically discouraged investment in Indian biopharma. A faster, globally credible regulatory process will attract multinational companies to set up operations in India and boost exports by earning global trust in Indian-approved products.
Background & Context: Why Now?
India's Shifting Disease Burden: India is witnessing a rapid epidemiological transition. Non-communicable diseases (NCDs) such as diabetes, cancer, cardiovascular disorders, and autoimmune conditions are increasingly replacing infectious diseases as the primary contributors to morbidity and mortality. This shift demands a robust availability of biologic medicines, which are complex, protein-based treatments essential for managing these conditions effectively.
The Biologics and Biosimilars Opportunity: Biologics are large-molecule drugs derived from living organisms — including monoclonal antibodies, vaccines, insulin, and cancer therapies. Biosimilars are their near-identical, more affordable versions produced after the original patent expires. The global biologics market is projected to cross $800 billion by 2030, making it one of the fastest-growing segments in healthcare.
India, known as the 'pharmacy of the world' for generic drugs, has untapped potential in this high-value space. The Biopharma SHAKTI scheme is designed to capture this opportunity by enabling domestic manufacturing and reducing heavy import dependence.
Current Import Dependence: Despite being a large pharmaceutical manufacturer, India heavily imports critical biologic medicines, especially for cancer, autoimmune, and rare diseases. This not only strains foreign exchange reserves but also keeps these life-saving medicines out of reach for millions due to high costs. Biopharma SHAKTI directly addresses this structural weakness.
Five Key Pillars of Biopharma SHAKTI
Pillar I – Domestic Manufacturing & Import Substitution
The scheme prioritises supporting domestic development and manufacturing of high-value biopharmaceutical products. By reducing import dependence, India can enhance its strategic position in the global biologics supply chain and ensure affordable access to critical medicines.
Pillar II – Expansion of NIPER Network
Three new National Institutes of Pharmaceutical Education & Research (NIPERs) will be established, and seven existing NIPERs will be upgraded. This is crucial for building specialised human capital in biopharma research, development, manufacturing, and regulation — addressing the current talent deficit in this niche sector.
Pillar III – Clinical Research Ecosystem
A large-scale clinical research infrastructure will be developed to boost India's capacity for advanced clinical trials. Historically, India has struggled to attract global clinical trials despite a large and diverse patient population. This pillar aims to change that narrative, enabling India to participate more actively in global drug development pipelines.
Pillar IV – Regulatory Strengthening via CDSCO
The Central Drugs Standard Control Organisation (CDSCO) will be reinforced through the creation of a dedicated Scientific Review Cadre. This will speed up regulatory approvals, making them faster and globally credible — a critical factor for attracting foreign investment and enabling domestic companies to gain international trust.
Pillar V – Innovation Funding & Startup Equity Support
The scheme includes early-stage innovation funding and structured equity support for startups and industry players, enabling promising drug candidates to move from concept through key development milestones. This bridges the critical funding gap in the Indian biopharma innovation pipeline.
Critical Analysis: Challenges Ahead
While Biopharma SHAKTI is a visionary step, several challenges must be addressed for it to deliver its full promise:
- Implementation Speed: Large government schemes in India often face delays in disbursement and on-ground execution. Robust monitoring mechanisms will be critical.
- Industry-Academia Gap: Merely establishing NIPERs is insufficient unless their curricula are closely aligned with industry requirements and global standards.
- Regulatory Culture Change: Faster approvals at CDSCO must not compromise safety standards. Balancing speed with scientific rigour is a delicate but essential task.
- Startup Funding Ecosystem: Early-stage biopharma startups face unique challenges — long development timelines, high capital requirements, and uncertain outcomes. Structured equity support must be designed carefully to avoid misallocation.
- Global Competition: Countries like the USA, China, South Korea, and Germany have multi-decade head starts in biologics. India will need sustained investment and policy consistency over 10–20 years, not just 5 years.
Key Facts for Competitive Exams
Quick-Revision Points
- Scheme: Biopharma SHAKTI | Outlay: ₹10,000 crore | Duration: 5 Years
- Focus Area: Biologics and Biosimilars manufacturing and innovation
- Announced by: Smt. Anupriya Patel (MoS, Chemicals & Fertilizers) in Rajya Sabha
- New NIPERs: 3 to be established | Existing NIPERs: 7 to be upgraded
- Regulator being strengthened: CDSCO (Central Drugs Standard Control Organisation)
- CDSCO's new feature: Dedicated Scientific Review Cadre for faster approvals
- India's disease shift: From communicable to non-communicable diseases (NCDs)
- Biologics treat: Diabetes, Cancer, Autoimmune disorders, Rare diseases
- Biosimilars = affordable versions of biologic drugs after patent expiry
- India's goal: Become global biopharma manufacturing and innovation hub
